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Objective: To identify the inﬂuence on radiosensitivity of lung glandular cancer cells
when excisions repair cross-complementing group1 (ERCC1) gene was silenced by tar-
geted siRNA.
Methods: siRNA which targeting to ERCC1 and control siRNA was designed and
synthesized. The human lung glandular cancer SPC-A-1 cells was transfected. A total of
56 nude mice were divided into two groups, and two kinds of SPC-A-1 cells were
transplanted to armpit of right forelimb, to establish the nude mice subcutaneous xeno-
transplanted tumor model of human lung glandular cancer cells. After the tumor was
developed, the nude mice were randomly divided into four groups and accepted different
doses of X-Ray radiation, then the change of tumor volume, survival time of mice in
every group were recorded and the average lifetime was calculated. Twenty-one days
later of X-ray experiment, two mice were taken and killed in each group and the tumors
organizations were stripped. The cell apoptosis rate and cell cycle distributions were
obtained by FCM (ﬂow cytometry).
Results: The volume of tumor which ERCC1 gene was silenced was less than single
irradiation group after X-ray irradiation, and the growth speed was slower and the lifetime
of mice was lengthened as well (P < 0.05). The cells apoptosis rate and the rate of G2/M
cells which ERCC1 gene was silenced were higher than the same dose control group and
the rate of G1 cells were lower, which indicated that the cells could be stopped at G2/M
point, the cell proliferation was inhibited, the cell apoptosis was promoted and the ra-
diation sensitivity was improved after the ERCC1 was silenced.
Conclusions: The radiation sensitivity of lung glandular tumor could be improved after
the ERCC1 gene was silenced by siRNA.1. Introduction
Lung glandular cancer is a kind of non small cell lung cancer.
In recent years, it has become a common subtype. Because of its
unique pathological features, its recurrence rate of is higher than
other types of lung cancer. It is difﬁcult to obtain ideal clinic
treatment effect [1,2]. Radiotherapy and chemotherapy are two
kinds of treatment for this malignant tumor. The main
mechanism is to disturb and destroy DNA transcription andreplication of cancer cells by radiation or drug. However, it is
hard to achieve ideal treatment effect because of drug
resistance or antagonism. Among them, the main mechanism
is the pathway of nucleotide excision repair (NER) [3].
Excision repair cross-complementing group1 (ERCC1), one
of the DNA repair gene, plays an important role in the process of
NER pathway and cell apoptosis [4]. Many studies have showed
that high expression of the gene can cause cancer cells produce
drug resistance and reduce the effect of radiotherapy. It has been
proved that the generation, development and prognosis of
tumors are related closely to the expression of this gene,
including colorectal cancer, ovarian cancer, non-small cell
lung cancer, pancreatic cancer, breast cancer, bile duct cancer etc
[5–10]. Furthermore, some studies have indicated that the
expression of ERCC1 is related to the radiosensitivity of
glioma and nasopharyngeal carcinoma [11,12]. In the study ofrticle under the CC BY-NC-ND license (http://
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lung glandular cancer patients [13], and its expression plays a
certain negative effect on clinical drug resistance of cisplatin
chemotherapeutics for curing lung glandular cancer [14,15]. But
so far, few research study the relationship between the gene
and radiosensitivity of lung glandular cancer. Therefore, the
author intends to study the effect of ERCC1 expression on the
radiosensitivity of lung glandular cancer cells through the
internal exposure transplant tumor model animal experiment,
and to explore whether it can be gene targets to enhance the
radiosensitivity of lung glandular cancer, so as to provide
experimental and theoretical basis for the clinical treatment of
lung glandular cancer.
2. Materials and methods
2.1. Materials
ERCC1 gene sequence is from GenBank, gene coding NM-
001983. siRNA which targeting to ERCC1 was designed ac-
cording to the reference [16], and synthesized by QIAGEN. The
sequence of designed siRNA-ERCC1 is 50-CAGGCGGCCC
CTCAGACCTAC-30; at the same time, a non speciﬁc siRNA
target sequence 50-GACTTCATAAGGCGCATGC-30 was
synthesized as negative control group. After Blast, the
sequence has no homology with mRNA of human gene.
2.2. Cell culture and transfection
Human lung glandular cancer SPC-A-1 cells used in the
study were from Shanghai Cell Bank of Chinese Academy of
Sciences. After recover the cryopreserved SPC-A-1 cell line, it
was conventionally cultured in RPMI solution containing 10%
fetal bovine serum, 100 kU/L penicillin and 100 mg/L strepto-
mycin (pH was adjusted to 7.2% with concentrated hydrochloric
acid) at 37 C, 5% CO2 and 90% relative humidity condition in
incubator. The cultured cells were divided into two groups
(marked as the ﬁrst group and the second group), and transfected
ERCC1-siRNA and negative control group respectively. When
transfected, SPC-A-1 cells in logarithmic phase were taken and
routinely inoculated in 6-well plates, 2 mL per hole, density
(1.5–2.5) × 105/mL, then incubated for about 10 min in a
constant-temperature incubator; 21 × 10−12 mol/L siRNA,
serum-free medium and HiperFect Transfection Reagent were
blended according to 4: 100: 6 in EP tube without RNA enzyme
and then incubated for about (5–l0) min at room temperature to
form complex. After that, every hole was added 110 mL mixture,
shook it to mix well and cultured for 24 h at 37 C, 5% CO2
condition in incubator.
2.3. Nude mice xenotransplanted tumor model
The nude mice were purchased from the animal experimental
center of Sun Yat-Sen University in China. The study was per-
formed after the mice were allowed to acclimate for 1 week in the
animal experimental center of Zhengzhou University. A total of
56micewere (4–6)weeks old, weighting (15–20) gwith half male
and half female. Mice were randomly divided into two groups, 28
in each group, inoculated with cultured cells of the ﬁrst group and
the second group respectively. Armpit of right forelimb of mice
which had been disinfected by alcohol were injected with2 × 10−6/mL cell suspension drew in 1 mL sterile syringes, each
only 0.2 mL. Then observe the tumor growth in mice. Average 7 d
later, tumor can be found in the mice subcutaneous tissues.
2.4. Radiation experiment
Fourteen days after completing the xenotransplanted tumor
model experiment, radiation experiment started. The mice of the
ﬁrst group and the second group were divided into four groups
(A1, B1, C1, D1 and A2, B2, C2, D2) and radiated according to
different total radiation dose. The total radiation dose of A1, A2
group was 3 GY, the total radiation dose of B1, B2 group was 9
GY, the total radiation dose of C1, C2 was 15 GY, and the total
radiation dose of D1, D2 group was 0 for receiving sham radi-
ation. Radiation was operated three times, once a day for three
days. The radiation source was 6 MV linear accelerator with
200 cGy/min dose rate and 10 cm × 15 cm radiation area. Before
radiation, nude mice were anesthetized by 2% pentobarbital
sodium injected in abdomens.
2.5. Tumor growth record
Before the radiation experiment, the tumor volume of mice
was measured every 3 d. Speciﬁcally, tumor volume was
measured with caliper including long diameter (a) and short
diameter (b), then calculated according to the formula
V = 0.5 × ab−2. The tumor growth curve was drawn from the
volume change of mice in each group, and the tumor growth in-
hibition rate was calculated according to the formula: tumor
growth inhibition rate = (tumor volume of the control group-tumor
volume of the experimental group)/tumor volume of the control
group × 100%. In this experiment, D2 group was the control
group. Radiation sensitivity was calculated in accordance with the
formula: radiation sensitivity = (the radiation effect of silenced
ERCC1)/(Single radiation effect) × 100%.Among them, the effect
referred to suppression (decrease) degree of tumor volume
compared with the control group (D2), such as the radiation
sensitivity under 3 GY radiation = (VA2 − VA1)/(VA2 − VD2).
Survival time ofmice in every groupwas recorded and the average
lifetime was calculated.
2.6. FCM experiment
Two mice in each group were killed 21 d after radiation
experiment was performed by anesthetizing and dislocating the
cervical vertebra; and the tumors organizations were stripped.
The cell apoptosis rate and cell cycle distributions were obtained
by FCM (model: EPICS-ELITE-ESP). The killed mice were not
included in the cumulative survival curve. All data is statistical
analyzed by SPSS19.0. P < 0.05 is considered to have signiﬁ-
cant difference.
2.7. Experimental ethics statement
All experiments in the study were conducted according to the
guidelines on animal healthcare and use of animal experimental
center of Zhengzhou University in Henan Province and
approved by local ethics committee. Besides, experiments were
conformed to the guidelines on healthcare and use of experi-
mental animals made by National Institutes of Health (Publica-
tion No. 85-23, revised in 1985).
Table 1
Change of tumor volume of mice in each group (mm−3).
Groups
Time (d) A1 B1 C1 D1 A2 B2 C2 D2
14 202.69 ± 12.35 198.89 ± 10.23 204.36 ± 14.35 215.36 ± 10.68 246.86 ± 14.36 253.67 ± 17.34 247.68 ± 16.41 256.78 ± 15.20
17 384.51 ± 18.65* 331.52 ± 15.69* 295.89 ± 14.32* 436.86 ± 26.34* 476.85 ± 29.65 454.65 ± 24.62* 387.85 ± 19.51* 514.36 ± 31.65
20 553.67 ± 28.63* 476.34 ± 26.38* 346.37 ± 19.54* 741.62 ± 36.84* 704.35 ± 32.51* 684.51 ± 29.63* 519.35 ± 21.36* 829.65 ± 37.65
23 843.67 ± 46.35* 563.24 ± 58.61* 403.96 ± 25.36* 1075.61 ± 59.62 1044.42 ± 54.62* 938.64 ± 48.51* 631.67 ± 39.12* 1194.32 ± 64.31
Growth
inhibition
ratio
29.36% 52.84% 66.18% 9.94% 12.55% 21.41% 47.11% –
26 1116.45 ± 52.34* 684.52 ± 33.65* 480.65 ± 21.63* 1559.37 ± 79.65 1423.21 ± 76.21* 1167.84 ± 62.31* 799.51 ± 21.68* 1751.63 ± 85.62
29 1287.42 ± 70.26* 795.69 ± 35.12* 521.38 ± 26.74* 2041.65 ± 106.31 1684.35 ± 84.21* 1456.38 ± 76.32* 850.42 ± 40.21* 2201.63 ± 103.21
32 1401.23 ± 79.21* 861.32 ± 48.53* 553.85 ± 29.31* 2435.41 ± 118.31 1863.42 ± 92.33* 1597.34 ± 75.31* 922.64 ± 46.31* 2563.25 ± 106.22
35 1466.42 ± 79.65* 893.85 ± 52.31* 624.67 ± 36.54* 2731.51 ± 125.61 2007.53 ± 109.65* 1657.83 ± 94.62* 1014.54 ± 54.62* 2815.32 ± 142.36
Growth
inhibition
ratio
47.91% 68.25% 77.81% 2.98% 28.69% 41.11% 63.96% –
*Compared with the control group, P < 0.05; A1: siRNA-ERCC1 + 3 GY irradiation; B1: siRNA-ERCC1 + 9 GY irradiation; C1: siRNA-ERCC1 + 15
GY irradiation; D1: siRNA-ERCC1 + 0 GY irradiation; A2: single 3 GY irradiation; B2: single 9 GY irradiation; C2: single 15 GY irradiation; D2:
blank control group.
Ying-Jie Ren, Xin-Quan Lv/Asian Paciﬁc Journal of Tropical Medicine 2016; 9(7): 672–6766743. Results
3.1. Tumor growth record
The volume change and the inhibition rate of tumor growth
in each group were seen in Table 1, and the radiosensitivity of
ERCC1 gene which was silenced was shown in Table 2. From
Table 1, we could see that after expression and irradiation of
ERCC1 gene which was silenced by targeted siRNA, the growth
of tumor tissue has been greatly inhibited (It showed signiﬁcant
difference between tumors volume in each group and D2 the
control group, P < 0.01), and the irradiation dose higher, inhi-
bition effect was more obvious (PA1B1 < 0.05, PA1C1 < 0.01,
PB1C1 < 0.05). After the ERCC1 gene was silenced, the sensi-
tivity of irradiation group was higher than single irradiationTable 2
Radiosensitivity with different radiation doses.
Time (d)
Radiation dose 14 17 20 23 26 29 32 35
3 GY 0.17 0.18 0.18 0.17 0.18 0.18 0.18 0.19
9 GY 0.21 0.24 0.25 0.31 0.28 0.30 0.29 0.27
15 GY 0.17 0.18 0.21 0.19 0.18 0.15 0.14 0.14
0 GY 0.16 0.15 0.11 0.10 0.11 0.07 0.05 0.03
Table 3
Change of survival mice numbers in each group.
Time (d) A1 B1 C1
30 5 5 5 5
32 5 5 5 5
34 5 5 5 5
36 5 5 5 5
38 5 5 5 4
40 5 5 5 4
42 4 5 5 3
44 4 4 4 2
46 3 4 4 1
48 2 3 3 0
50 1 3 2 0
Average lifetime 48.2 ± 4.3* 51.4 ± 6.1** 56.6 ± 4.7** 43.8
*Compared with the control group, P < 0.05; **Compared with the controlgroup, and the radiosensitivity effect was most obvious when the
irradiation dose was 9 GY.
The average lifetime and cumulative survival time of mice in
each group were shown in Table 3. From the cumulative sur-
vival time schedule, we could see after radiotherapy, the lifetime
of mice in each group were extended in some degree compared
to the control group (P < 0.05).
3.2. FCM experiment
The results of cell apoptosis rate obtained by FCM were as
follows: A1: (23.21% + 4.32%); B1: (30.47% + 4.12%); C1:
(36.60% + 5.21%); D1: (10.81% + 3.55%); A2: (13.86% +Groups
D1 A2 B2 C2 D2
5 5 5 5
5 5 5 5
5 5 5 5
5 5 5 4
5 5 5 4
4 5 5 3
4 4 5 2
2 3 4 1
2 2 3 0
1 2 3 0
0 1 2 0
± 3.5 44.8 ± 3.3* 47.2 ± 4.3* 49.6 ± 4.1** 42.6 ± 3.4
group, P < 0.01.
Table 4
The proportion of cell cycle distribution in each group (%).
Groups G1 S G2
A1 35.69 40.57 23.74
B1 26.35 39.44 34.21
C1 19.64 35.04 45.32
D1 54.21 32.23 13.56
A2 48.62 36.04 15.34
B2 42.29 39.08 18.63
C2 36.94 38.70 24.36
D2 71.61 21.16 7.23
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(5.24% + 1.41%). The results of cell cycle distribution were
shown in Table 4. We could see that after ERCC1 gene was
silenced by targeted siRNA (A2, A3 group), the apoptosis rate of
them was higher than the control group, and the proportion of
cells decreased at G2/M point.
4. Discussion
The basic principle of radiotherapy is destructing nucleotide
replication of tumor cells by ionizing radiation, and ERCC1 is
one of the most important genes involved in nucleotide damage
repair. Many studies show that ERCC1 can reduce the chemo-
therapy and radiotherapy effect of many tumors because of its
impact on the nucleotide repair pathway [17]. In this study, the
author inhibited the expression of ERCC1 gene in lung
glandular cancer cells by small interfering RNA technology,
and then irradiated xenotransplanted tumor model of lung
glandular cancer cells to study the relationship between
ERCC1 gene and the radiosensitivity of lung glandular cancer.
From the experimental results, we could see that after
transfection siRNA-ERCC1 cells and independent sequence
control group cells were transplanted into subcutaneous tissue
of nude mice and radiated under different doses, the growth
status had a signiﬁcant statistical difference. The inhibition
rate of tumor volume and growth of transfection siRNA-
ERCC1 was signiﬁcantly lower than the control group, which
meant siRNA-ERCC1 could promote the apoptosis of lung
glandular cancer cells under ray radiation, inhibits tumor
growth and have certain radiosensitivity effect. When
irradiation dose was 15 GY, radiosensitivity of it was lower
than that of 9 GY radiation dose which proved that higher
radiation dose didn't mean higher radiosensitivity. It provided
new ideas and methods for the molecular targeted radiation of
lung glandular cancer.
The reason why silenced ERCC1 can improve the radiosen-
sitivity of lung glandular cancer cells is worth exploring. Studies
have shown that ERCC1 can rapidly repair damaged DNA at G2/
M point and enter a state of normal proliferation [18]. Therefore,
from Table 4, it can be seen that after silenced ERCC1
expressed, cells were stopped at G2/M point, could not be nor-
mally proliferated and induced apoptosis. The researchers
believed that ERCC1 played a dual role in tumor tissue. In some
tumor tissues, when the cancer cells appeared, cell proliferation
became abnormal. At this time, ERCC1 played repair function of
nucleotide to resist malignant proliferation of tumor [19]; On the
other hand, in the course of treatment of tumors, platinum based
chemotherapy drugs or radiation destroyed the replication of
nucleotide in tumor cells, and repair function played by
ERCC1 also had an antagonistic effect [20,21]. That was
because whether chemotherapy or radiotherapy, cancer cells
were killed in non-normal means which caused harm to
normal tissues and cells while inhibiting tumor growth. Physi-
ological reactions not only determined organisms taking certain
measures to repair these damages, but also produced drug
resistance or radiation antagonism. When silenced ERCC1 was
expressed and radiation dose was 9 GY (not 15 GY), mice cu-
mulative survival curve area was the largest, which might
because high radiation dose increased the radiosensitivity, but
damage the other organs of mice, thus the cumulative survival
time of mice was reduced. Therefore, the detailed mechanism ofERCC1 in different tumor tissues has not been clearly deﬁned
[22], so it still needs further experiment and research.
This study inhibited the expression of ERCC1 gene in lung
glandular cancer cells through small interfering RNA technol-
ogy, establish mice xenotransplanted tumor model of lung
glandular cancer cells, and evaluate the growth condition of
xenotransplanted tumor model. After irradiation, the prolifera-
tion activity and apoptosis rate were measured and found that
compared with the control group, siRNA-Bcl-2 cells could
effectively improve the apoptosis rate of gastric cancer cells,
which proved that the expression of silenced Bcl-2 gene could
enhance the radiosensitivity of gastric cancer cells.
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